Swissmedic approves Tasigna for first-line Ph+ CML

Swissmedic approved Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) for first-line treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in chronic phase. The BC...